OpportunityJOBPublic signal53 days ago
Sr./Ex. Director or VP, Clinical Scientist (PhD or PharmD equivalent)
Hexagon Bio is hiring for this role on its own job board, after raising $62M.
Who they want
Approach preferences not yet specified
Hexagon Bio
Hexagon Bio is a biopharmaceutical company providing new payload mechanisms for antibody-drug conjugates (ADCs). From its funding announcement.
In their own words
What Hexagon Bio says it is doing
Public signal Described in the funding announcement as "biopharmaceutical company providing new payload mechanisms for antibody-drug conjugates (ADCs)". Source
ProductResearch and development
Public signal Read from the company's own description of what the funding supports.
Why now
Where Hexagon Bio is today
Hexagon Bio announced a Series C round of $62M on 26 October 2026, led by The Column Group.
Latest round
Series C
Amount
$62M
Announced
26 October 2026
Headquarters
Menlo Park, USA
Sector
Biotech & Pharma
Growth stage
Series C+
Investors
Also participating
Relevant leadership
CEO Maureen Hillenmeyer
Momentum AfterRaise intelligence
AfterRaise Score
79
Building momentum
1 funding signal in the last 90 days
Arriving with the signals layer
- Hiring momentum Open roles and hiring pace
- Market expansion New offices and new countries
- Leadership Executive appointments
- Product activity Launches and releases
Since the raise
What has happened since
- 26 October 2026$62M Series CLed by The Column Group.
Public signal The timeline currently holds funding events, because those are the signals AfterRaise observes today. Hiring, leadership, expansion and product events join it with the signals layer.
What may happen next
What this raise could create
AfterRaise intelligenceNot a statement of fact
What may happen next
- Product launches and new tiers
- Product leadership hiring
- Research programme expansion
- Scientific team growth
Opportunities this could create
- Clinical operations
- Scientific hiring
- Licensing and BD partnerships
- Product leadership
- Design partners
Based on the Biotech & Pharma sector, a Series C+ round and the priorities the company itself set out. Not a statement of fact.
Medium momentum3 connected signals
- 26 October 2026$62M Series C announced
- 26 October 2026Stated priority: product
- 26 October 2026Stated priority: research and development
High momentum means several meaningful company changes have occurred in a short period. Signals here are funding events and the priorities the company stated; hiring, leadership and expansion detection join with the signals layer.
Open to
What Hexagon Bio is open to
Not yet specified
Hexagon Bio has not told AfterRaise which approaches it welcomes. Until it does, we do not assume. Offers to help are held and shown to the company, and the company decides whether to open a conversation.
Work here? Set your preferencesOpportunities
Ways to work with Hexagon Bio
Helpful contributors
People who have contributed here
Nobody yet
When someone offers help and the company says it was useful, they appear here. Reputation on AfterRaise is built from contributions the company confirmed, not from follower counts.
Do you work at Hexagon Bio?
Claim your company profile.
This page was created from publicly available information. A verified representative corrects the record, says what the company is building next and chooses which conversations it welcomes.
Someone else requesting access does not give them ownership. Every representative is verified by a person before access is granted.
Maintaining your own company profile is free. A founder, CEO or authorised senior colleague can represent the company.
Also moving